Bolar and Vitarine sued again
Executive Summary
Generic firms sued in class action filed in Pennsylvania federal court by SmithKline Beecham shareholders, Bolar disclosed June 27. Complaint alleges violations of racketeering and federal securities statutes "in connection with allegations that Bolar and Vitarine submitted false or misleading information to FDA in gaining approval" of generic versions of Dyazide, Bolar notes. Smith-Kline Beecham also filed a complaint against the two firms and Schein alleging unfair competition ("The Pink Sheet" June 18, T&G-8).